Aethlon Medical Retained Earnings (Accumulated Deficit) 2010-2024 | AEMD

Aethlon Medical retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Aethlon Medical Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024 $-155
2023 $-142
2022 $-130
2021 $-120
2020 $-112
2019 $-106
2018 $-99
2017 $-94
2016 $-87
2015 $-82
2014 $-75
2013 $-61
2012 $-57
2011 $-48
2010 $-43
2009 $-38
Aethlon Medical Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $-160
2024-06-30 $-157
2024-03-31 $-155
2023-12-31 $-152
2023-09-30 $-149
2023-06-30 $-146
2023-03-31 $-142
2022-12-31 $-140
2022-09-30 $-137
2022-06-30 $-133
2022-03-31 $-130
2021-12-31 $-127
2021-09-30 $-124
2021-06-30 $-122
2021-03-31 $-120
2020-12-31 $-118
2020-09-30 $-115
2020-06-30 $-113
2020-03-31 $-112
2019-12-31 $-110
2019-09-30 $-109
2019-06-30 $-108
2019-03-31 $-106
2018-12-31 $-104
2018-09-30 $-102
2018-06-30 $-101
2018-03-31 $-99
2017-12-31 $-98
2017-09-30 $-97
2017-06-30 $-96
2017-03-31 $-94
2016-12-31 $-92
2016-09-30 $-91
2016-06-30 $-89
2016-03-31 $-87
2015-12-31 $-85
2015-09-30 $-84
2015-06-30 $-83
2015-03-31 $-82
2014-12-31 $-81
2014-09-30 $-79
2014-06-30 $-78
2014-03-31 $-75
2013-12-31 $-67
2013-09-30 $-65
2013-06-30 $-62
2013-03-31 $-61
2012-12-31 $-59
2012-09-30 $-59
2012-06-30 $-58
2012-03-31 $-57
2011-12-31 $-52
2011-09-30 $-52
2011-06-30 $-51
2011-03-31 $-48
2010-12-31 $-51
2010-09-30 $-49
2010-06-30 $-46
2010-03-31 $-43
2009-12-31 $-42
2009-09-30 $-40
2009-06-30 $-39
2009-03-31 $-38
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.005B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $531.004B 21.35
Cigna Group (CI) United States $89.704B 11.73
Humana (HUM) United States $33.448B 15.23
Centene (CNC) United States $29.186B 8.56
Molina Healthcare (MOH) United States $16.159B 12.85
Select Medical Holdings (SEM) United States $4.792B 16.60
Joint (JYNT) United States $0.164B 99.54